FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2530482928> ?p ?o ?g. }

• W2530482928 endingPage "1796" @default.
• W2530482928 startingPage "1785" @default.
• W2530482928 abstract "Abstract Purpose: Neuroblastoma is treated with aggressive multimodal therapy, yet more than 50% of patients experience relapse. We recently showed that relapsed neuroblastomas frequently harbor mutations leading to hyperactivated ERK signaling and sensitivity to MEK inhibition therapy. Here we sought to define a synergistic therapeutic partner to potentiate MEK inhibition. Experimental Design: We first surveyed 22 genetically annotated human neuroblastoma-derived cell lines (from 20 unique patients) for sensitivity to the MEK inhibitor binimetinib. After noting an inverse correlation with sensitivity to ribociclib (CDK4/6 inhibitor), we studied the combinatorial effect of these two agents using proliferation assays, cell-cycle analysis, Ki67 immunostaining, time-lapse microscopy, and xenograft studies. Results: Sensitivity to binimetinib and ribociclib was inversely related (r = −0.58, P = 0.009). MYCN amplification status and expression were associated with ribociclib sensitivity and binimetinib resistance, whereas increased MAPK signaling was the main determinant of binimetinib sensitivity and ribociclib resistance. Treatment with both compounds resulted in synergistic or additive cellular growth inhibition in all lines tested and significant inhibition of tumor growth in three of four xenograft models of neuroblastoma. The augmented growth inhibition was attributed to diminished cell-cycle progression that was reversible upon removal of drugs. Conclusions: Here we demonstrate that combined binimetinib and ribociclib treatment shows therapeutic synergy across a broad panel of high-risk neuroblastoma preclinical models. These data support testing this combination therapy in relapsed high-risk neuroblastoma patients, with focus on cases with hyperactivated RAS–MAPK signaling. Clin Cancer Res; 23(7); 1785–96. ©2016 AACR." @default.
• W2530482928 created "2016-10-21" @default.
• W2530482928 creator A5000850685 @default.
• W2530482928 creator A5005796905 @default.
• W2530482928 creator A5005797590 @default.
• W2530482928 creator A5008979088 @default.
• W2530482928 creator A5016326595 @default.
• W2530482928 creator A5017202683 @default.
• W2530482928 creator A5025118565 @default.
• W2530482928 creator A5031062394 @default.
• W2530482928 creator A5034411606 @default.
• W2530482928 creator A5037219238 @default.
• W2530482928 creator A5042276874 @default.
• W2530482928 creator A5046454516 @default.
• W2530482928 creator A5048910641 @default.
• W2530482928 creator A5061418960 @default.
• W2530482928 creator A5065761868 @default.
• W2530482928 creator A5068529122 @default.
• W2530482928 creator A5068771969 @default.
• W2530482928 creator A5068961742 @default.
• W2530482928 creator A5075837989 @default.
• W2530482928 creator A5087956058 @default.
• W2530482928 date "2017-04-01" @default.
• W2530482928 modified "2023-10-14" @default.
• W2530482928 title "Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma" @default.
• W2530482928 cites W1532769922 @default.
• W2530482928 cites W1915238740 @default.
• W2530482928 cites W1978073487 @default.
• W2530482928 cites W1995364339 @default.
• W2530482928 cites W1996213181 @default.
• W2530482928 cites W1997727251 @default.
• W2530482928 cites W2030646897 @default.
• W2530482928 cites W2044025814 @default.
• W2530482928 cites W2077945404 @default.
• W2530482928 cites W2104096565 @default.
• W2530482928 cites W2118023637 @default.
• W2530482928 cites W2118874870 @default.
• W2530482928 cites W2119279070 @default.
• W2530482928 cites W2122583405 @default.
• W2530482928 cites W2130465135 @default.
• W2530482928 cites W2130925781 @default.
• W2530482928 cites W2132546867 @default.
• W2530482928 cites W2133382697 @default.
• W2530482928 cites W2140657586 @default.
• W2530482928 cites W2144999788 @default.
• W2530482928 cites W2145927254 @default.
• W2530482928 cites W2151322893 @default.
• W2530482928 cites W2157789221 @default.
• W2530482928 cites W2160981405 @default.
• W2530482928 cites W2164349814 @default.
• W2530482928 cites W2178424952 @default.
• W2530482928 cites W2213548494 @default.
• W2530482928 cites W2261411200 @default.
• W2530482928 cites W2289394228 @default.
• W2530482928 cites W2345781825 @default.
• W2530482928 doi "https://doi.org/10.1158/1078-0432.ccr-16-1131" @default.
• W2530482928 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27729458" @default.
• W2530482928 hasPublicationYear "2017" @default.
• W2530482928 type Work @default.
• W2530482928 sameAs 2530482928 @default.
• W2530482928 citedByCount "64" @default.
• W2530482928 countsByYear W25304829282017 @default.
• W2530482928 countsByYear W25304829282018 @default.
• W2530482928 countsByYear W25304829282019 @default.
• W2530482928 countsByYear W25304829282020 @default.
• W2530482928 countsByYear W25304829282021 @default.
• W2530482928 countsByYear W25304829282022 @default.
• W2530482928 crossrefType "journal-article" @default.
• W2530482928 hasAuthorship W2530482928A5000850685 @default.
• W2530482928 hasAuthorship W2530482928A5005796905 @default.
• W2530482928 hasAuthorship W2530482928A5005797590 @default.
• W2530482928 hasAuthorship W2530482928A5008979088 @default.
• W2530482928 hasAuthorship W2530482928A5016326595 @default.
• W2530482928 hasAuthorship W2530482928A5017202683 @default.
• W2530482928 hasAuthorship W2530482928A5025118565 @default.
• W2530482928 hasAuthorship W2530482928A5031062394 @default.
• W2530482928 hasAuthorship W2530482928A5034411606 @default.
• W2530482928 hasAuthorship W2530482928A5037219238 @default.
• W2530482928 hasAuthorship W2530482928A5042276874 @default.
• W2530482928 hasAuthorship W2530482928A5046454516 @default.
• W2530482928 hasAuthorship W2530482928A5048910641 @default.
• W2530482928 hasAuthorship W2530482928A5061418960 @default.
• W2530482928 hasAuthorship W2530482928A5065761868 @default.
• W2530482928 hasAuthorship W2530482928A5068529122 @default.
• W2530482928 hasAuthorship W2530482928A5068771969 @default.
• W2530482928 hasAuthorship W2530482928A5068961742 @default.
• W2530482928 hasAuthorship W2530482928A5075837989 @default.
• W2530482928 hasAuthorship W2530482928A5087956058 @default.
• W2530482928 hasBestOaLocation W25304829281 @default.
• W2530482928 hasConcept C121608353 @default.
• W2530482928 hasConcept C126322002 @default.
• W2530482928 hasConcept C143998085 @default.
• W2530482928 hasConcept C2776715637 @default.
• W2530482928 hasConcept C2779707156 @default.
• W2530482928 hasConcept C2781230642 @default.
• W2530482928 hasConcept C2781249067 @default.
• W2530482928 hasConcept C502942594 @default.
• W2530482928 hasConcept C54355233 @default.

• next